Mini Review

You have full text access to this OnlineOpen article

Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention

  1. Hang Xiao1,†,*,
  2. Chung S. Yang2

Article first published online: 11 JUN 2008

DOI: 10.1002/ijc.23718

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 983–990, 1 September 2008

Additional Information

How to Cite

Xiao, H. and Yang, C. S. (2008), Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. Int. J. Cancer, 123: 983–990. doi: 10.1002/ijc.23718

Author Information

  1. 1

    Department of Food Science, University of Massachusetts, Amherst, MA

  2. 2

    Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

  1. †

    Fax: +413-545-1262

*Department of Food Science, University of Massachusetts, 100 Holdsworth Way, Amherst, MA 01003, USA

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 11 JUN 2008
  3. Manuscript Accepted: 7 MAY 2008
  4. Manuscript Received: 20 MAR 2008

Funded by

  • Department of Food Science, University of Massachusetts, Amherst

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (316K)

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
    Direct Link:
  • 2
    Sporn MB,Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002; 2: 537–43.
  • 3
    Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78: 199–334.
  • 4
    Blais L,Desgagne A,LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363–8.
  • 5
    Graaf MR,Beiderbeck AB,Egberts AC,Richel DJ,Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388–94.
  • 6
    Friis S,Poulsen AH,Johnsen SP,McLaughlin JK,Fryzek JP,Dalton SO,Sorensen HT,Olsen JH. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643–7.
    Direct Link:
  • 7
    Olsen JH,Johansen C,Sorensen HT,McLaughlin JK,Mellemkjaer L,Steffensen FH,Fraumeni JF,Jr. Lipid-lowering medication and risk of cancer. J Clin Epidemiol 1999; 52: 167–9.
  • 8
    Kaye JA,Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004; 90: 635–7.
  • 9
    Poynter JN,Gruber SB,Higgins PD.Almog R,Bonner JD,Rennert HS,Low M,Greenson JK,Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184–92.
  • 10
    Jacobs EJ,Rodriguez C,Brady KA,Connell CJ,Thun MJ,Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst 2006; 98: 69–72.
  • 11
    Dale KM,Coleman CI,Henyan NN,Kluger J,White CM. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74–80.
  • 12
    Bonovas S,Filioussi K,Flordellis CS,Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol 2007; 25: 3462–8.
  • 13
    Khurana V,Bejjanki HR,Caldito G,Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131: 1282–8.
  • 14
    Khurana V,Caldito G,Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology 2008; 71: 118–22.
  • 15
    Platz EA,Leitzmann MF,Visvanathan K,Rimm EB,Stampfer MJ,Willett WC,Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819–25.
  • 16
    Murtola TJ,Tammela TL,Lahtela J,Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226–32.
  • 17
    Farwell WR,Scranton RE,Lawler EV,Lew RA,Brophy MT,Fiore LD,Gaziano JM. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100: 134–9.
  • 18
    Setoguchi S,Glynn RJ,Avorn J,Mogun H,Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007; 115: 27–33.
  • 19
    Vinogradova Y,Hippisley-Cox J,Coupland C,Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133: 393–402.
  • 20
    Thun MJ,Henley SJ,Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–66.
  • 21
    Agrawal A,Fentiman IS. NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 2008; 62: 444–449.
    Direct Link:
  • 22
    Thun MJ,Namboodiri MM,Calle EE,Flanders WD,Heath CW,Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322–7.
  • 23
    Bonovas S,Filioussi K,Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005; 60: 194–203.
    Direct Link:
  • 24
    Harris RE,Beebe-Donk J,Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007; 3: 328–34.
  • 25
    Olsen JH,Friis S,Poulsen AH,Fryzek J,Harving H,Tjonneland A,Sorensen HT,Blot W. Use of NSAIDs, smoking and lung cancer risk. Br J Cancer 2008; 98: 232–7.
  • 26
    Hernandez-Diaz S. and Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007; 120: 1565–72.
    Direct Link:
  • 27
    Dasgupta K,Di Cesar D,Ghosn J,Rajan R,Mahmud S,Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130–5.
  • 28
    Jacobs EJ,Thun MJ,Bain EB,Rodriguez C,Henley SJ,Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007; 99: 608–15.
  • 29
    Duan L,Wu AH,Sullivan-Halley J,Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 2008; 17: 126–34.
  • 30
    Giardiello FM,Hamilton SR,Krush AJ,Piantadosi S,Hylind LM,Celano P,Booker SV,Robinson CR,Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313–6.
  • 31
    Labayle D,Fischer D,Vielh P,Drouhin F,Pariente A,Bories C,Duhamel O,Trousset M,Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–9.
  • 32
    Nugent KP,Farmer KC,Spigelman AD,Williams CB,Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618–9.
    Direct Link:
  • 33
    Cruz-Correa M,Hylind LM,Romans KE,Booker SV,Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122: 641–5.
  • 34
    Giardiello FM,Yang VW,Hylind LM,Krush AJ,Petersen GM,Trimbath JD,Piantadosi S,Garrett E,Geiman DE,Hubbard W,Offerhaus GJ,Hamilton SR. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054–9.
  • 35
    Sandler RS,Halabi S,Baron JA,Budinger S,Paskett E,Keresztes R,Petrelli N,Pipas JM,Karp DD,Loprinzi CL,Steinbach G,Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–90.
  • 36
    Baron JA,Cole BF,Sandler RS,Haile RW,Ahnen D,Bresalier R,McKeown-Eyssen G,Summers RW,Rothstein R,Burke CA,Snover DC,Church TR, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9.
  • 37
    Benamouzig R,Deyra J,Martin A,Girard B,Jullian E,Piednoir B,Couturier D,Coste T,Little J,Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328–36.
  • 38
    Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000–16.
  • 39
    Steinbach G,Lynch PM,Phillips RK,Wallace MH,Hawk E,Gordon GB,Wakabayashi N,Saunders B,Shen Y,Fujimura T,Su LK,Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–52.
  • 40
    Bertagnolli MM,Eagle CJ,Zauber AG,Redston M,Solomon SD,Kim K,Tang J,Rosenstein RB,Wittes J,Corle D,Hess TM,Woloj GM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873–84.
  • 41
    Arber N,Eagle CJ,Spicak J,Racz I,Dite P,Hajer J,Zavoral M,Lechuga MJ,Gerletti P,Tang J,Rosenstein RB,Macdonald K, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885–95.
  • 42
    Bresalier RS,Sandler RS,Quan H,Bolognese JA,Oxenius B,Horgan K,Lines C,Riddell R,Morton D,Lanas A,Konstam MA,Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
  • 43
    Kerr DJ,Dunn JA,Langman MJ,Smith JL,Midgley RS,Stanley A,Stokes JC,Julier P,Iveson C,Duvvuri R,McConkey CC. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007; 357: 360–9.
  • 44
    Solomon SD,McMurray JJ,Pfeffer MA,Wittes J,Fowler R,Finn P,Anderson WF,Zauber A,Hawk E,Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80.
  • 45
    Psaty BM,Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006; 355: 950–2.
  • 46
    Ladabaum U,Scheiman JM,Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003; 114: 546–54.
  • 47
    Arguedas MR,Heudebert GR,Wilcox CM. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Aliment Pharmacol Ther 2001; 15: 631–8.
    Direct Link:
  • 48
    Jalving M,Koornstra JJ,De Jong S,De Vries EG,Kleibeuker JH. Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005; 21: 321–39.
    Direct Link:
  • 49
    Demierre MF,Higgins PD,Gruber SB,Hawk E,Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930–42.
  • 50
    Sacks FM,Pfeffer MA,Moye LA,Rouleau JL,Rutherford JD,Cole TG,Brown L,Warnica JW,Arnold JM,Wun CC,Davis BR,Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9.
  • 51
    Swamy MV,Cooma I,Reddy BS,Rao CV,Lamin B. Caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimens. Int J Oncol 2002; 20: 753–9.
  • 52
    Hoffmeister M,Chang-Claude J,Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer 2007; 121: 1325–30.
    Direct Link:
  • 53
    Flick ED,Habel LA,Chan KA,Van Den Eeden SK,Quinn VP,Haque R,Orav EJ,Seeger JD,Sadler MC,Quesenberry CP,Jr.,Sternfeld B,Jacobsen SJ, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218–25.
  • 54
    Agarwal B,Rao CV,Bhendwal S,Ramey WR,Shirin H,Reddy BS,Holt PR. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117: 838–47.
  • 55
    Feleszko W,Jalili A,Olszewska D,Mlynarczuk I,Grzela T,Giermasz A,Jakobisiak M. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 2002; 9: 879–85.
  • 56
    Xiao H,Zhang Q,Lin Y,Reddy BS,Yang CS, Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer, 2008.
    Direct Link:
  • 57
    Zheng X,Cui XX,Avila GE,Huang MT,Liu Y,Patel J,Kong AN,Paulino R,Shih WJ,Lin Y,Rabson AB,Reddy BS, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007; 13: 5480–7.
  • 58
    Reddy BS,Wang CX,Kong AN,Khor TO,Zheng X,Steele VE,Kopelovich L,Rao CV. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006; 66: 4542–6.
  • 59
    Swamy MV,Patlolla JM,Steele VE,Kopelovich L,Reddy BS,Rao CV. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006; 66: 7370–7.
  • 60
    Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15: 1398–407.
  • 61
    Agarwal B,Bhendwal S,Halmos B,Moss SF,Ramey WG,Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 1999; 5: 2223–9.
  • 62
    Graaf MR,Richel DJ,van Noorden CJ,Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30: 609–41.
  • 63
    Zhuang L,Kim J,Adam RM,Solomon KR,Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115: 959–68.
  • 64
    Perez-Sala D,Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199: 1209–15.
  • 65
    Prasanna P,Thibault A,Liu L,Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996; 66: 710–6.
    Direct Link:
  • 66
    Tsujii M,Kawano S,DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336–40.
  • 67
    Sheng H,Shao J,Morrow JD,Beauchamp RD,DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362–6.
  • 68
    Liu XH,Kirschenbaum A,Yao S,Stearns ME,Holland JF,Claffey K,Levine AC. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999; 17: 687–94.
  • 69
    Grosch S,Maier TJ,Schiffmann S,Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98: 736–47.
  • 70
    Kardosh A,Blumenthal M,Wang WJ,Chen TC,Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004; 3: 55–62.
  • 71
    Grosch S,Tegeder I,Niederberger E,Brautigam L,Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15: 2742–4.
  • 72
    Arico S,Pattingre S,Bauvy C,Gane P,Barbat A,Codogno P,Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613–21.
  • 73
    Kulp SK,Yang YT,Hung CC,Chen KF,Lai JP,Tseng PH,Fowble JW,Ward PJ,Chen CS. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64: 1444–51.
  • 74
    Hanada M,Feng J,Hemmings BA, Structure, regulation and function of PKB/AKT–a major therapeutic target. Biochim Biophys Acta 2004; 16972: 3–16.
  • 75
    Jendrossek V,Handrick R,Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003; 17: 1547–9.
  • 76
    Kim SH,Song SH,Kim SG,Chun KS,Lim SY,Na HK,Kim JW,Surh YJ,Bang YJ,Song YS. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol 2004; 130: 551–60.
  • 77
    Liu X,Yue P,Zhou Z,Khuri FR,Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96: 1769–80.
  • 78
    Johnson AJ,Hsu AL,Lin HP,Song X,Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002; 366: 831–7.
  • 79
    Kundu N,Smyth MJ,Samsel L,Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 2002; 76: 57–64.
  • 80
    Goel A,Chang DK,Ricciardiello L,Gasche C,Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 2003; 9: 383–90.
  • 81
    Luciani MG,Campregher C,Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007; 28: 2207–17.
  • 82
    Stark LA,Din FV,Zwacka RM,Dunlop MG. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001; 15: 1273–5.
  • 83
    Maier TJ,Janssen A,Schmidt R,Geisslinger G,Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005; 19: 1353–5.
  • 84
    Dihlmann S,Klein S,Doeberitz Mv MK. Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin. Mol Cancer Ther 2003; 2: 509–16.
  • 85
    Wei D,Wang L,He Y,Xiong HQ,Abbruzzese JL,Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004; 64: 2030–8.
  • 86
    Lin HP,Kulp SK,Tseng PH,Yang YT,Yang CC,Chen CS,Chen CS. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 2004; 3: 1671–80.
  • 87
    Peluffo GD,Stillitani I,Rodriguez VA,Diament MJ,Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 2004; 110: 825–30.
    Direct Link:
  • 88
    Ostrowski J,Wocial T,Skurzak H,Bartnik W. Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer 2003; 88: 1143–51.
  • 89
    Lee HC,Park IC,Park MJ,An S,Woo SH,Jin HO,Chung HY,Lee SJ,Gwak HS,Hong YJ,Yoo DH,Rhee CH, et al. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 2005; 94: 597–610.
    Direct Link:
  • 90
    Borthwick GM,Johnson AS,Partington M,Burn J,Wilson R,Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006; 20: 2009–16.
  • 91
    Sahai E,Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2: 133–42.
  • 92
    Adnane J,Bizouarn FA,Qian Y,Hamilton AD,Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 1998; 18: 6962–70.
  • 93
    Huang M. and Prendergast GC. RhoB in cancer suppression. Histol Histopathol 2006; 21: 213–8.
  • 94
    Sheng H,Shao J,Kirkland SC,Isakson P,Coffey RJ,Morrow J,Beauchamp RD,DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254–9.
  • 95
    Hsi LC,Baek SJ,Eling TE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 2000; 256: 563–70.
  • 96
    Shishodia S. and Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004; 64: 5004–12.
  • 97
    Jang MH,Shin MC,Lim S,Han SM,Park HJ,Shin I,Lee JS,Kim KA,Kim EH,Kim CJ. Bee venom induces apoptosis and inhibits expression of cyclooxygenase-2 mRNA in human lung cancer cell line NCI-H1299. J Pharmacol Sci 2003; 91: 95–104.
View Full Article (HTML) Get PDF (316K)